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Background:Angiotensin-converting-enzyme inhibition reduces the risk of cardiovascular events at a group level.
Presumably, the absolute effect of treatment varies between individuals.We sought to developmultivariable pre-
diction scores to estimate individual treatment effect of perindopril in patients with stable coronary artery dis-
ease (sCAD).
Methods: In EUROPA trial participants, we estimated the individual patient 5-year absolute risk reduction
(ARR) of major adverse cardiovascular events(MACE) by perindopril. Predictions were based on a new
Coxproportional-hazards model with clinical characteristics and an external risk score in combination with the
observed relative risk reduction. Second, a genetic proﬁle modifying the relative efﬁcacy of perindopril was
added. The individual patient ARR was deﬁned as the difference in MACE risk with and without treatment. The
group level impact of selectively treating patients with the largest predicted treatment effect was evaluated
using net beneﬁt analysis.
Results: The risk score combining clinical and genetic characteristics estimated the 5-year absolute treatment ef-
fect to be absent or adverse in 27% of patients. On the other hand, the risk score estimated a small 5-year ARR of
≤2% (NNT5 ≥ 50) in 20% of patients, a modest ARR of 2–4% (NNT5 25–50) in 26%, and a large ARR of ≥4%
(NNT5≤ 25) in 28%. The external risk score yielded similar predictions. Selective prediction-based treatment re-
sulted in higher net beneﬁt compared to treat everyone at any treatment threshold.
Conclusion: A prediction score combining clinical characteristics and genetic information can quantify the ARR of
MACE by perindopril for individual patients with sCAD and may be used to guide treatment decisions.
Trial registration number: ISRCTN37166280© 2014 Elsevier Ireland Ltd. All rights reserved.1. Introduction
Activation of the renin–angiotensin system (RAS) has an important
role in the development of cardiovascular disease [1]. The beneﬁcial ef-
fects of blocking RAS by angiotensin-converting-enzyme inhibitors
(ACE-i) were ﬁrst demonstrated in patients with heart failure [2,3]. Fur-
ther studies showed the efﬁcacy of ACE-i in awider range of clinical con-
ditions and these agents are currently recommended for the treatmentMedicine, University Medical
erlands.
eren).
.of patients with hypertension, recent myocardial infarction and stable
coronary artery disease (sCAD) [4]. One of the landmark trials in pa-
tients with sCAD is the EUROPA trial, evaluating the effect of perindopril
on the occurrence of new major adverse cardiovascular events (MACE)
in sCAD patients without heart failure. The trial found an average rela-
tive reduction in MACE of 20% [5]. The average 4-year absolute treat-
ment effect of perindopril was 2%, translating to an average 4-year
number-needed-to-treat (NNT4) of 50 patients to prevent one event
[5]. In search of patients who are most likely to beneﬁt, stratiﬁed analy-
ses based on clinical characteristics and levels of baseline risk revealed
similar relative risk reductions across all subgroups [6,7]. However, ge-
netic variations in pharmacodynamic pathways affected by ACE-i were
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located in the angiotensin-II type 1 receptor and bradykinin type 1 re-
ceptor genes were associated with a larger, smaller or even adverse ef-
fect of perindopril. To quantify the effect of treatment for individual
patients, relative risk reductions need to be interpreted in combination
with absolute event risks [9–12]. In general, patients with higher base-
line risk tend to beneﬁt more from treatment in terms of absolute risk
reduction [13,14]. Baseline risk is determined by the combined action
of multiple risk factors such as age, cholesterol and blood pressure
[15]. In the present study we sought to develop prediction scores
based on a combination of multiple patient-speciﬁc clinical and genetic
characteristics to estimate the absolute risk reduction of MACE with
perindopril for individual patients with sCAD. In clinical practice, these
scores can be used to quantify treatment beneﬁt at an individual patient
level and to guide treatment decisions.
2. Methods
The design, rationale and outcomes of the EUROPA trial and the PERindopril GENetic
association study (PERGENE) substudy have been described elsewhere [16,17]. Brieﬂy, the
EUROPA trial was a randomized, double blind study evaluating the effect of perindopril
8 mg once daily versus placebo on major cardiovascular adverse events (MACE) compris-
ing cardiovascular death, myocardial infarction (MI), and resuscitated cardiac arrest in
12,218 patients with sCAD. Eligible patients were men and women of 18 years or
older, with evidence of coronary heart disease documented by previous MI (N3 months
before screening), percutaneous or surgical coronary revascularization (N6 months
before screening), angiographic evidence of at least 70% narrowing of at least one
major coronary artery, or a history of typical chest pain inmale patients with an abnormal
stress test. Exclusion criteria included clinically evident heart failure, planned revascular-
ization procedure, hypotension (sitting systolic blood pressure b110 mm Hg), uncon-
trolled hypertension (systolic blood pressure N180 mm Hg and/or diastolic blood
pressure N100 mm Hg), use of ACE-i or angiotension-2 receptor blockers in the
last month, renal insufﬁciency (serum creatinine N150 μmol/L), and serum potassium
N5.5 mmol/L. PERGENE is a substudy of the EUROPA trial designed to investigate whether
commongenetic variation is related to risk of future events andmodiﬁes the treatment ef-
fect of perindopril [8]. Blood samples were received from 10060 patients and 8726 pa-
tients had complete genotype data on rs275651, rs5182 and rs12050217, the three
single nucleotide polymorphisms (SNPs) identiﬁed to modify the effect of perindopril [8,
18]. A genetic proﬁle was constructed by counting the number of unfavorable alleles
and grouping them into 3 categories:≤1 unfavorable allele (reference), 2 unfavorable al-
leles and≥3 unfavorable alleles. Approval for the trial was obtained from the institutional
ethics committee of each center and all participants provided written informed consent.
2.1. Model derivation
The individual patient absolute treatment effect onMACEwas estimatedwith clinical
models and with models combining clinical and genetic characteristics. First, we ﬁtted a
new Cox proportional hazards model (i.e. EUROPA score) based on a set of clinical charac-
teristics together with a treatment variable (placebo vs. active treatment) [7]. The pre-
speciﬁed predictors were: sex, age, systolic blood pressure, cholesterol, body-mass index
(BMI), diabetes, smoking, estimated glomerular ﬁltration rate (eGFR; by CKD-EPI equa-
tion [19]), symptomatic CAD, family history of CAD, prior stroke or transient ischemic at-
tack, prior MI, prior coronary revascularization and prior peripheral arterial disease and
treatment status. Restricted cubic splines were used to assess the linearity assumption
for continuous predictors. If the association between a continuous predictor and the out-
come was not linear, the predictor was transformed to improve model ﬁt [20,21]. As a re-
sult, age, BMI andeGFRwere includedboth as linear and squared terms.We used the Lasso
method (i.e. penalizedpartialmaximum likelihoodwith a restriction on the sumof the ab-
solute coefﬁcients of standardized predictors) to select the model and shrink the model
coefﬁcients to minimize over-optimism [22,23]. The interaction between treatment and
baseline riskwas evaluated but not signiﬁcant [24]. Themodelwasﬁtted for the prediction
of 4.3-year (median follow-up) risks and extrapolated to yield 5-year estimates. The indi-
vidual patient absolute risk reduction (ARR) was deﬁned as the difference between esti-
mated on-treatment and off-treatment risk.
Second, we evaluated the combination of clinical and genetic characteristics to predict
absolute treatment effect for individual patients. Hereto, we expanded the EUROPAmodel
with a genetic proﬁle (3-level categorical variable) and the interaction between
perindopril treatment and this proﬁle (i.e. EUROPA-GEN score). Again, the Lasso method
was used to select the model and shrink the coefﬁcients. The clinical model was ﬁtted in
the full EUROPA cohort, whereas the model with additional genetic variables was ﬁtted
in the PERGENE subsample. All models were evaluated in the PERGENE subsample to en-
sure comparability of results.
Supplementary analyses encompassed the use of an externally developed risk algo-
rithm, the SMART risk score, together with the relative treatment effect observed in the
trial [25]. The baseline risk of the SMART risk score was recalibrated to the 5-year disease
incidence of the target population. Data on HDL cholesterol, high sensitivity C-reactive
protein and history of abdominal aortic aneurysm were not available and were set tozero. In addition, the genetic proﬁle and the treatment interaction of perindopril with
this proﬁle were added to this model. The Lasso method was used to select and shrink
the newly added variables.
Data was missing in 10.1% of participants for the variable ‘years since ﬁrst vascular
event’ and in b1% for all other variables. Missing data were reduced by single imputation
methods using predictive mean matching [26].
2.2. Model performance
Discrimination of the risk scores was assessed by calculation of Harrell's c-statistic
[21]. Calibration of predicted risk was assessed by plotting observed 4.3-year event free
survival against the average predicted 4.3-year event free survival within deciles and
was formally checked by the Gronnesby and Borgan test [27,28]. Since the actual interest
was the accuracy of predicted ARR rather than risk, we also assessed whether predicted
ARR was in agreement with observed ARR by comparing observed survival within quin-
tiles of patients with similar estimated ARR from the placebo and intervention group. Op-
timally, the observed survival difference between these paired quintiles should be similar
to the estimated ARR.
2.3. Distribution of absolute treatment effect and net beneﬁt
The distributions of predicted individual 5-year ARR ofMACEwere displayed in histo-
grams. Next, we evaluated the incremental value of applying therapeutic prediction
models in clinical practice using the net beneﬁt method [29]. The calculation of net beneﬁt
is based on the weighing of positive and negative effects of treatment. The severity of
treatment disadvantages is expressed relative to the outcome by a threshold NNT. For ex-
ample, a 5-year threshold NNT of 50 implies that the disadvantages of treating 50 patients
for 5 years are considered to be well balanced by the beneﬁt obtained by preventing one
outcome. Net beneﬁt is calculated as the observedARR in patients forwhom the treatment
recommended by the prediction algorithm is congruent with randomized allocation
minus the disadvantages of treatment. The latter is deﬁned as the proportion of patients
treated weighted by the inverse of the threshold NNT (net beneﬁt = ARR — proportion
of patients treated * [1/thresholdNNT]). Net beneﬁt can be interpreted as the excess num-
ber of events prevented per 100 patients on top of the minimally required number of
events prevented to offset treatment disadvantages. We considered the following treat-
ment strategies; (i) treat no one, (ii) treat everyone or (iii) prediction-based treatment
(i.e. selective treatment of patientswhose predicted treatment effect exceeds the speciﬁed
thresholdNNT). Lastly, we showed the impact of using a prediction-based treatment strat-
egy in clinical practice. Statistical analyseswere conducted in R, version 2.15.2 (RDevelop-
ment Core Team, Vienna, Austria) with Harrell's Regression Modelling Strategies package
and Goeman's ‘penalized’ package.
3. Results
Baseline characteristics of the PERGENE participants (n = 8726)
are shown in Table 1 and are similar to those of the whole EUROPA
population. During a median follow-up of 4.3 years 794 major cardio-
vascular events occurred. The hazard ratio of the overall treatment ef-
fect for MACE was 0.80 (95% CI 0.71–0.91) favoring treatment with
perindopril.
3.1. Model derivation & performance
3.1.1. Clinical model
The EUROPA models are presented in Box 1. All predictors in the
EUROPA model were retained. Detailed statistics are presented in Sup-
plement Table 1. Discrimination was moderate with a c-statistic of
0.67 [95% CI 0.65–0.69]. The EUROPA model showed good risk calibra-
tion (p-value 0.34) (Supplement Fig. 1). The ARR calibration plot
showed an acceptable agreement between predicted and observed
ARR (Fig. 1). The externally developed SMART model is shown in Sup-
plement Box 1.
3.1.2. Clinical model combined with genetic proﬁle
During model selection all clinical, genetic and interaction variables
were retained in the EUROPA-GEN score (Box 1). Detailed statistics are
available in Supplement Table 1. Discriminationwasmoderate with a c-
statistic of 0.68 [95% CI 0.66–0.70]. The EUROPA-GEN models showed
good visual calibration (although contradicted by a p-value of 0.01 by
the formal test statistics) (Supplement Fig. 1). Notably, the ARR calibra-
tion plot of the expandedmodel showed awider range of predicted and
observed treatment effects. The agreement between predicted and ob-
served absolute treatment effect was generally close (Fig. 1). The
Table 1
Baseline characteristics of 8726 EUROPA participants with available genetic proﬁle and
stratiﬁed according to predicted 5-year absolute risk reduction (ARR) by the EUROPA-
GEN score.
Total population
(n = 8726)
b2% ARR
(n = 4077)
≥2% ARR
(n = 4649)
Clinical characteristics
Age (years) 59.8 (9.3) 58.8 (8.9) 60.7 (9.5)
Gender, % female 14.5 17.3 12.0
Hypertension, % 28.5 27.2 29.7
Diabetes, % 12.7 8.9 16.1
Current smoking, % 14.7 12.8 16.5
Duration of vascular disease, years 4.3 (4.7) 3.9 (4.3) 4.6 (4.9)
Body mass index (kg/m2) 27.5 (3.5) 27.3 (3.2) 27.6 (3.7)
Symptomatic CAD†, % 25.4 19.8 30.4
Family history of CAD, % 27.2 27.2 27.2
Prior myocardial infarction, % 65.4 59.9 70.1
Prior revascularization, % 54.6 59.7 50.1
Prior stroke or TIA, % 3.5 2.6 4.4
Prior PVD, % 7.4 5.1 9.4
Total cholesterol (mmol/L) 5.4 (1.0) 5.3 (1.0) 5.5 (1.1)
eGFR (mL/min/1.73 m2) 75 (64–87) 77(66–89) 73 (62–86)
Randomized treatment, % 49.7 50.4 49.1
Systolic blood pressure (mm Hg) 137(15) 136 (15) 138 (15)
Diastolic blood pressure (mm Hg) 82 (8) 82 (8) 82 (8)
Genetic proﬁle
≤1 unfavorable allele, % 41.1 2.7 74.7
2 unfavorable alleles, % 32.4 40.5 25.3
≥3 unfavorable alleles, % 26.5 56.8 0
Summary statistics for continuous variables are presented as mean (standard deviation)
or as median (interquartile range). Categorial variables are presented as precentages.
ARR: absolute risk reduction. eGFR: estimated glomerular ﬁltration rate estimated by
CKD-EPI equation, LDL: low density lipoprotein, HDL: high density lipoprotein, TIA: tran-
sient ischemic attack, PVD: peripheral vascular disease.
† Agina pectoris or previous heart failure.
Box 1
The EUROPA risk scores
Individual patient off−treatment risk : “treatment” ¼ 0 NOð Þ
Individual patient on−treatment risk : “treatment” ¼ 1 YESð Þ:
A) EUROPA score
5−year MACE risk %ð Þ ¼ 1 – 0:91exp A þ 6:415ð Þ
 
 100%
A = age * −0.1324+ age2* 0.0013 + female sex *
−0.4643+ SBP * 0.0041+ total cholesterol * 0.1499+ eGFR
eGFR*−0.0339+eGFR2* 0.0002+BMI *−0.2590+BMI2 *
0.0049+diabetes * 0.4481+ current smoking * 0.3876+ fam-
ily history of CAD * 0.1662 + prior MI * 0.3671 + prior TIA
or stroke * 0.4446 + prior PVD * 0.5092 + prior coronary
revascularization *−0.2235 + symptomatic CAD * 0.3981 +
treatment *−0.2167
B) EUROPA-GEN score
5−year MACE risk %ð Þ ¼ 1 – 0:91exp A þ 7:390ð Þ
 
 100%
A = age * −0.1351 + age2* 0.0013 + female sex *
−0.5474+ SBP * 0.0040+ total cholesterol * 0.1237+ eGFR
eGFR*−0.0358+eGFR2* 0.0002+BMI *−0.2958+BMI2 *
0.0056+diabetes * 0.4673+ current smoking * 0.4449+ fam-
ily history of CAD * 0.0791 + prior MI * 0.4055 + prior TIA
or stroke * 0.4433 + prior PVD * 0.5340 + prior coronary revas-
cularization *−0.1582+ symptomatic CAD * 0.4080+ genetic
profile 1 *−0.2062+genetic profile 2 *−0.5112+treatment *
−0.5466 + treatment & 2 unfavorable alleles * 0.3207 + treat-
ment &≥3 unfavorable alleles * 0.7498
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statistics are presented in Supplement Table 1.
3.2. Distribution of treatment effect of perindopril
The EUROPA score predicted a small 5-year ARR≤2% (NNT5≥ 50) in
60.1% of patients. The predicted 5-year ARR was between 2 and 4%
(NNT5 25–50) in 33.5% of patients and ≥4% (NNT5 ≤ 25) in 6.4% of pa-
tients (Fig. 2). The SMART score identiﬁed similar proportions of pa-
tients in these categories of absolute treatment effect (Supplement
Fig. 2).
The EUROPA-GEN score predicted an absent or adverse treatment
effect in 26.5% of patients (Fig. 2). These adverse responders were char-
acterized by an unfavorable genetic proﬁle (i.e. ≥3 unfavorable alleles)
and were at higher cardiovascular risk when treated with perindopril
compared with placebo. Alternatively, the EUROPA-GEN score predict-
ed a large 5-year ARR of ≥4% (NNT5 ≤ 25) in 27.7% of patients. The
SMART-GEN score identiﬁed similar proportions per category (Supple-
ment Fig. 2). Table 1 displays the characteristics of patients stratiﬁed ac-
cording to predicted treatment effect, showing higher risk factor levels
and a skewed genetic proﬁle in patients with a larger ARR.
3.3. Net beneﬁt and clinical consequences of individualized prediction of
treatment effect of perindopril
Across the entire range of 5-year treatment threshold NNTs, the clin-
ical EUROPA score was not associated with higher net beneﬁt at a pop-
ulation level compared to treating everyone or no one (Fig. 3). Hence,
this model does not succeed in accurately directing treatment to sCAD
patients who can anticipate the largest beneﬁt from perindopril. On
the other hand, the EUROPA-GEN score showed higher net beneﬁt com-
pared to treating everyone or no one across a wide range of treatment
thresholds (Fig. 3). Even if the treatment threshold is inﬁnite, suggesting
one is prepared to treat a vast number of patients (e.g. N250) for 5 years
to prevent a single event, prediction-based treatment is superior. This
could be expected since prediction-based treatment limits prescription
to the 73.5% of sCAD patients with an estimated positive effect, while
withholding treatment for the 26.5% of patients with an estimated ad-
verse or null effect (Table 2). Results were similar for the SMART risk
scores with and without genetic characteristics (Supplement Fig. 3).
When restricting treatment to patients with larger predicted treatment
effects, the average 5-year NNT among treated patients could be re-
duced from 42 to 12 depending on the choice of treatment threshold
(Table 2).
4. Discussion
In the present study we demonstrated that therapeutic prediction
models based on clinical and genetic characteristics were able to quan-
tify the ARR ofmajor cardiovascular events by perindopril for individual
patients with sCAD. Of all participants, 27% had an absent or adverse
treatment effect whereas 28% had a large estimated 5-year ARR of
≥4% (NNT5≤ 25). Selective treatment of patients based on a prediction
score can result in a more optimal trade-off between the number of
events prevented and number of patients treated.
Guidelines recommend ACE-i in patients with sCAD, especially if
there are co-existing conditions such as hypertension, reduced left ven-
tricular ejection fraction or chronic kidney disease [30,31]. These recom-
mendations are based on the overall results of large randomized clinical
trials showing reductions in cardiovascular events and mortality [5,32,
33]. Even if the relative risk reduction is constant, the absolute risk re-
duction with treatment varies and is likely to increase with baseline
event risk. However, in the present study the relative efﬁcacy of
perindopril was inﬂuenced by the patients' genetic proﬁle and patients
with similar baseline risks had different risk reductions. Consequently,
the clinical scores with just a single treatment variable (i.e. active vs.
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Fig. 1. Calibration plots of predicted versus observed 4.3 year absolute risk reduction (ARR) of major cardiovascular events (MACE) in quintiles for different prediction scores.
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tient treatment beneﬁt as was illustrated by the weak relation between
predicted and observed ARR. Conversely, the prediction scores with
both clinical and genetic variables combined the patient's baseline risk
with an efﬁcacy measure (i.e. hazard ratio) that was applicable to the
patient's speciﬁc genetic proﬁle and yielded accurate estimates of indi-
vidual treatment effect. The patient-speciﬁc ARR can be translated to an
individualized NNT (iNNT), which refers to the number of patients with
the same characteristics as the patient under care that require treat-
ment for a speciﬁc time to prevent one event (Box 3)[11].
The effect of implementing an individualized treatment strategy in
clinical practice was evaluated at a group level [29]. Selective drug pre-
scription, based on an individualized treatment prediction algorithm,
can direct treatment to those patients who might expect the largest
beneﬁt and least harm of treatment. The choice of an appropriate treat-
ment threshold is difﬁcult as the threshold comprises adverse effects of
the drug, the inconvenience of daily taking a drug and monetary costs.
Notably, the frequency of adverse effects is difﬁcult to estimate based
on trial results as only patientswho tolerated perindoprilwere random-
ized after a run-in period. For randomized patients, the difference in ad-
herence to allocated therapy was 3.4% in the EUROPA [5]. Hence,
treating for example 100 patients in clinical practice will result in at5−y treatment effect (ARR)
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Fig. 2. Distribution of 5-year absolute risk reduction (ARR) of major cardiovasculaleast 3 patients experiencing an adverse effect prompting them to dis-
continue the drug. Secondly, disadvantages include the inconveniences
of 100 patients who need to take perindopril daily for 5 years (i.e. 500
person-years of treatment). Thirdly, there are economic costs of
perindopril prescription. At a 5-year threshold NNT of 100, we consider
all the negative effects of treating 100 patients together to be balanced
by the prevention of, for example, one MACE. We acknowledge that
this summary of positive and negative effects is incomplete and subject
to interpretation. Therefore, we speciﬁed a range of treatment thresh-
olds, deﬁned as the number of patients one would be willing to treat
to prevent one adverse cardiovascular outcome, to allow clinicians
and patients to make their own appraisal of treatment risks and bene-
ﬁts. Further, the treatment thresholdmay change over time as for exam-
ple drug costs decrease. A prediction-based treatment strategy using the
EUROPA-GEN or SMART-GEN treatment score yielded the highest net
beneﬁt at any treatment threshold considered. Hence, implementing
these scores in clinical practice can improve the balance between num-
ber of patients treated and number of adverse cardiovascular outcomes
prevented, irrespective of the treatment threshold.
Strengths of the present study include the large number of available
events to derive treatment scores, the use of both clinical and genetic
data and the use of existing and newly developed prediction scores.5−y treatment effect (ARR)
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Fig. 3.Net beneﬁt curves of different treatment strategies for major cardiovascular events
(MACE). Net beneﬁt is calculated as the observed ARR ofMACE (%) in patients whose ran-
domized allocation is similar to recommendations fromthe treatment scoreminus thedis-
advantages of treatment. The disadvantages of treatment are expressed as the proportion
of patients receiving treatment weighted by the threshold NNT. First, a (range of) thresh-
old NNT should be determined and next the strategy associated with the highest net ben-
eﬁt for this (range of) threshold can be extracted from the graph. The threshold NNT may
vary among clinicians and patients. The treat all line originates at the average ARR ob-
served in the trial, since the negative effects of treatment are assumed to be zero at an in-
ﬁnite threshold NNT5. Treat none is associated with zero net beneﬁt.
Box 3
Predicted 5-year absolute risk reduction of MACE when treated with
perindopril for two different patient profiles.
Patient A
A asymptomatic 60-year old non-smoking male patient without di-
abetes, an SBP of 130mmHg, a BMI of 25 kg/m2, no family histo-
ry of CAD, no prior MI, no prior stroke, no prior PVD, a CABG
procedure 2 years ago, a TC of 6 mmol/L, an eGFR of 60 ml/min
and 2 unfavorable alleles.
➔ 5-year ARR with perindopril is 1.1% (individual NNT5 = 88)
Patient B
A symptomatic 60-year old smokingmale patientwith diabetes, an
SBP of 150 mm Hg, a BMI of 30 kg/m2, no family history of CAD,
no prior MI, no prior stroke, no prior PVD, no prior revasculariza-
tion, a TC of 6 mmol/L, an eGFR of 60ml/min and≤1 unfavorable
allele.
➔ 5-year ARR with perindopril is 11.6% (individual NNT5 = 9)
198 J. van der Leeuw et al. / International Journal of Cardiology 182 (2015) 194–199Further, the present study is theﬁrst to provide a treatment score to cal-
culate an individualized estimate of the effect of perindopril. These esti-
mates may help physicians to engage patients in shared-decision
making by facilitating an appraisal of risks and beneﬁts of treatment at
an individual patient level. In addition, we evaluated the group level ef-
fects of implementing a prediction score in clinical practice, which is rel-
evant to guideline makers. Potential limitations of our study also merit
consideration. One of themain concerns of developing a new prediction
score is that a score is likely to perform optimistically if tested in the
sample from which it was derived [20]. To reduce optimism, we used
penalized model estimation based on cross-validation and used a limit-
ed number of prespeciﬁed predictors. The effect-size of treatment inter-
actions by genetic proﬁle could not be based on external data, although
the magnitude and directions of the interactions have been reproduced
in ex-vivo experiments and in the PROGRESS trial [8,34]. In addition, the
risk of chance ﬁndings was greatly reduced by only evaluating SNPs in
12 candidate genes that are part of biological pathways affected by
ACE-i. This is different from genome wide association studies without
a speciﬁc biological hypothesis. Other potential limitations include the
generalizability of ﬁndings. As with the average trial result, the treat-
ment prediction scores apply to patients who would be eligible forTable 2
Consequences for clinical practice based on EUROPA-GEN score.
5-year threshold NNT Tx-strategy Tx-rate
– Treat all 100%
250 Prediction-based Tx 73%
100 Prediction-based Tx 70%
50 Prediction-based Tx 53%
25 Prediction-based Tx 28%
17 Prediction-based Tx 13%
Tx: Treatment. *Percentage of total population treated with perindopril. †Predicted average red
patients actively treated with perindopril.inclusion in the EUROPA trial. Since the number of female participants
was relatively small, the models should be used with caution in female
patients. Further, current predictions apply to a 5-year time period. In
addition, the individualized effect estimates were not accompanied by
uncertainty margins. In the setting op medical decision making, the in-
terpretation of such margins can be difﬁcult since the point estimate is
the most likely value for an individual patient [35]. Further, the use of
a prediction score to select patients for treatment is more time consum-
ing than treating everyone. However, the widespread use of electronic
patient records in clinical practice may facilitate the use of prediction
rules by automatically feeding information to risk calculators (Supple-
ment Fig. 4). Nevertheless, genetic information regarding the SNPs
thatmodify treatment effect is not routinely assessed in clinical practice.
Given the promising results and potential clinical implications, external
validation of treatment prediction algorithms including genetic infor-
mation should be pursued.
In conclusion, treatment effect prediction scores based on clinical
and genetic characteristics can quantify the ARR ofmajor cardiovascular
events for individual patients with sCAD. The use of a therapeutic pre-
diction score in clinical practice can improve the balance between the
number of patients treated and the number of events prevented com-
pared with one-size-ﬁts-all approaches such as treating no one or
everyone.Funding
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